Founded 2015, Oxford Science Enterprises: £1.1bn AUM. 58-person team (14 partners). 99 portfolio companies; 2 IPOs, 13 acquisitions. Notable exits: Latent Logic (Waymo, 2018), DJS Antibodies (AbbVie, 2022). Portfolio includes YASA, PepGen, Brill Power, Oxford VR. Value-add: founder talent recruitment, strategic advisory, long-term co-investment, academic IP access.
Investment Focus
Investment Thesis
Exclusive University of Oxford spinout investor. Seed-to-growth stage: pre-seed (£50k-£750k grants), seed (avg £4.45M), Series A (avg £20.9M), through to exit. Focus: life sciences (38 investments), deep tech (quantum, nuclear fusion), AI/software, health tech. Avoids non-Oxford-linked companies. Differentiated by: evergreen patient capital model; co-equity with university; rare NAV financing (raised £175m via Goldman/Deutsche Bank 2025); 100+ portfolio firms, 2 IPOs, 13 exits.
Interested in connecting?
Visit their website or reach out directly.